Nomikos, N., Naoum, P., Athanasakis, K. and Kyriopoulos, I 
ORCID: 0000-0002-3932-8228
(2024)
Cost-effectiveness analysis of filgotinib versus tofacitinib as first-line treatments for rheumatoid arthritis in Greece.
Value in Health, 27 (12, Supplement).
S80 - S80.
ISSN 1098-3015
Abstract
Rheumatoid arthritis (RA) is a chronic, progressive disease characterized by joint inflammation and systemic effects. This study evaluates the cost-effectiveness of filgotinib, a selective oral JAK1 inhibitor with a proven efficacy and safety profile, combined with methotrexate for treating patients with moderate to severe active RA who had an inadequate response to disease-modifying antirheumatic drugs (DMARDs) in Greece, compared to tofacitinib.
| Item Type: | Article |
|---|---|
| Divisions: | Health Policy |
| Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology |
| Date Deposited: | 11 Mar 2025 08:39 |
| Last Modified: | 11 Mar 2025 08:57 |
| URI: | http://eprints.lse.ac.uk/id/eprint/127535 |
Actions (login required)
 |
View Item |
